Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Japanese Patients with NNS/CANDLE, SAVI, and AGS
NCT04517253Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in Nakajo-Nishimura syndrome (NNS), Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature, STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutières syndrome (AGS), sponsored by Eli Lilly and Company. Started Oct 2020; status: terminated.
02
Drugs
baricitinib
03
Conditions
Nakajo-Nishimura syndrome (NNS)Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatureSTING-associated vasculopathy with onset in infancy (SAVI)Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on NCT04517253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517253.